• Telix is a global radiopharmaceutical company with an established commercial footprint and deep theranostic pipeline
• Telix's growth strategy focuses on expanding global infrastructure, growing its precision medicine business, and delivering its late-stage therapeutic pipeline
• Telix is investing in production infrastructure, localized manufacturing, and strategic partnerships to ensure reliable and scalable product delivery globally

Telix Pharmaceuticals, a global radiopharmaceutical company, is hosting an Investor Day in New York City on June 11, 2025. The event will feature presentations from Telix's management team and independent expert speakers, covering key trends in radiopharmaceutical development, the company's precision medicine and therapeutic pipeline, and its plans for future growth. Telix's growth strategy focuses on three key areas: expanding its global infrastructure for product delivery, growing its industry-leading precision medicine business, and delivering its late-stage therapeutic pipeline. The company is investing in production infrastructure, including cyclotron installations and strategic partnerships, to ensure reliable and scalable product delivery across major global markets. Telix's differentiated approach to theranostic radiopharmaceuticals, commitment to precision medicine, and specialized commercial teams provide the company with competitive advantages. The Investor Day will highlight Telix's progress in advancing its pipeline, including the expansion of its PSMA imaging market and opportunities in urologic oncology, glioblastoma, and pan-cancer indications. The event will also feature presentations from independent expert speakers, who will provide insights on the latest developments and unmet needs in their respective fields. The agenda covers a range of topics, including key trends in radiopharmaceutical development, the evolution of manufacturing processes, and the advancement of targeting vectors for improved tumor binding and pharmacokinetics.Overall, the Telix Investor Day aims to showcase the company's strategic vision, competitive strengths, and growth opportunities as it continues to lead the development and commercialization of theranostic radiopharmaceuticals.